Pericardial tamponade in coronary interventions: Morbidity and mortality
Catheterization and Cardiovascular Interventions · 2024
DOI: 10.1002/ccd.31213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Saurabh Deshpande und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, India. Hauptthemen laut MEDLINE: Cardiac Tamponade, Hospital Mortality, Databases, Factual, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Cardiac tamponade or pericardial tamponade (PT) can be a complication following invasive cardiac procedures.
Methods
Patients who underwent various procedures in the cardiac catheterization lab (viz. coronary interventions) were identified using the International Classification of Diseases, Ninth and Tenth Edition, Clinical Modification (International classification of diseases [ICD]‐9‐Clinical modification [CM] and ICD‐10‐CM, respectively) from the Nationwide Inpatient Sample (NIS) database. Patient demographics, presence of comorbidities, PT‐related events, and in‐hospital death were also abstracted from the NIS database.
Results
The frequency of PT‐related events in the patients undergoing CI from 2010 to 2017 ranged from 3.3% to 8.4%. Combined in‐hospital mortality/morbidity of PT‐related events were higher with increasing age (odds ratio [OR] [95% CI]: chronic total occlusion (CTO) = 1.19 [1.10‐1.29]; acute coronary syndrome (ACS) = 1.21 [1.11‐1.33], both p < 0.0001) and female sex (OR [95%CI]: CTO = 1.70 [1.45‐2.00]; ACS = 1.72 [1.44‐2.06], both p < 0.0001). In‐hospital mortality related to PT‐related events was found to be 8.5% for coronary procedures. In‐hospital mortality was highest amongst the patients undergoing percutaneous transluminal coronary angioplasty (PTCA) for ACS (ACS vs. non‐CTO PTCA vs. CTO PTCA: 15.7% vs. 10.4% and 14.4%, p < 0.0001 and ACS vs. non‐CTO PTCA vs. CTO PTCA: 12.1% vs. 8.1% and 5.6%, p = 0.0001, respectively).
Conclusions
In the real‐world setting, PT‐related events in CI were found to be 3.3%−8.4%, with in‐hospital mortality of 8.5%. The patients undergoing PTCA for ACS were found to have highest mortality. Older patients undergoing CTO PTCA independently predicted higher mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, India.
- Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Perioperative and Critical Care Management, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Cardiology, Northumbria Healthcare NHS Foundation Trust, Newcastle, UK.
- Independent Reseracher, Mauritius.
- Rawalpindi Medical University, Rawalpindi, Pakistan.
ORCID-Profile: Saurabh Deshpande, Mushood Ahmed
Zitieren
APA
Deshpande, S., Sawatari, H., Rangan, K., Buchade, A., Ahmed, R., Ramphul, K., Ahmed, M., Khanji, M. Y., Somers, V. K., Shahid, F., Chahal, A. A., & Padmanabhan, D. (2024). Pericardial tamponade in coronary interventions: Morbidity and mortality. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31213
Vancouver
Deshpande S, Sawatari H, Rangan K, Buchade A, Ahmed R, Ramphul K, et al. Pericardial tamponade in coronary interventions: Morbidity and mortality. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31213
BibTeX
@article{Deshpande2024,
author = {Deshpande, Saurabh and Sawatari, Hiroyuki and Rangan, Kapil and Buchade, Anusha and Ahmed, Raheel and Ramphul, Kamleshun and Ahmed, Mushood and Khanji, Mohammed Y and Somers, Virend K and Shahid, Farhan and Chahal, Anwar A and Padmanabhan, Deepak},
title = {Pericardial tamponade in coronary interventions: Morbidity and mortality},
journal = {Catheterization and Cardiovascular Interventions},
year = {2024},
doi = {10.1002/ccd.31213}
}
EUVIMED